Anthropic's IPO: Can Wall Street Buy What It Cannot Control?

In August, Anthropic handed prospective investors the strongest financial disclosure any frontier AI lab has produced. 

As indicated by Bloomberg, the total revenue was in excess of $11.5 billion in the second quarter.

This figure represents 14 times the revenue of $787 million earned in the second quarter of 2025.

Sequential growth was also steep, up more than 140% from $4.73 billion in the first quarter.  

The company also reported positive adjusted operating income for the first time.

A day earlier, the Financial Times reported that half a dozen Anthropic backers expect an October listing above $2 trillion. 

That would surpass SpaceX (SPCX) as the largest IPO ever conducted. There has been no target set by senior executives, even privately. 

The figure is derived from investor projections, not management projections. The Wall Street Journal has since reported a November target. 

The interesting question is not whether the growth is real. It is what a public shareholder actually receives in exchange for the capital.

The Financial Case Rests on One Ratio

Revenue scale is not enough to merit a trillion-dollar multiple. Unit economics do. 

The Wall Street Journal reported in May that Anthropic spent 71 cents on compute for every revenue dollar in the first quarter. 

The company guided that ratio to 56 cents in the second quarter. This 15-cent change makes the company profitable, moving it from operating losses to an adjusted operating profit. 

Metric	Q2 2025	Q1 2026	Q2 2026 (preliminary)
Revenue	$787 million	$4.73 billion	Above $11.5 billion
Sequential growth	n/a	n/a	Above 140%
Compute cost per revenue dollar	Not disclosed	71 cents	56 cents (guided)
Adjusted operating income	Negative	Negative	Positive

Investors project annualized revenue of $100 billion to $120 billion by December. Against that base, $2 trillion implies roughly 20 times forward revenue. 

Palantir (PLTR) and Nebius (NBIS) have traded near 55 times sales this year. The multiple looks defensible only if the growth rate holds.

Skeptics have a fair counterargument. Amazon (AMZN) carries a market capitalization near $2.9 trillion on quarterly revenue above $200 billion and operating income of $27.5 billion. 

Its $62.6 billion second-quarter net income was inflated by a $53.4 billion gain, mostly on its Anthropic stake. 

Anthropic would arrive at a comparable valuation on a fraction of that revenue. The second-quarter figures are also preliminary and unaudited.

Capital Intensity Forces the Listing

Anthropic is not going public because it wants retail shareholders. It is going public because private syndicates can no longer fund the buildout.

The company has committed more than $100 billion to Amazon Web Services over ten years for up to five gigawatts of Trainium capacity. 

It expanded its arrangement with Alphabet (GOOGL) and Broadcom (AVGO) in April for multi-gigawatt TPU capacity from 2027. 

Microsoft (MSFT) invested alongside Nvidia (NVDA) in November 2025 against roughly $30 billion of Azure commitments. 

Those obligations are contractual and long-dated, while the revenue supporting them is not.

The window is favorable. IPO issuance globally has hit $256.4 billion in 2026, which is the best year since 2021.

The precedent is less encouraging. SpaceX priced at $135 on June 11 for a $1.77 trillion valuation, peaked at $225.64 on June 16, then traded below its offering price by mid-July. Public markets repriced a hyped listing in about five weeks.

Sovereign Risk Became an Operating Line Item

Anthropic is attempting a record listing while litigating against the United States government.

The Department of Defense designated the company a supply chain risk in March after Anthropic refused unrestricted military access to Claude. 

Anthropic sued on First Amendment and due process grounds. CFO Krishna Rao stated the action could cut 2026 revenue by billions of dollars.

A California district judge granted a preliminary injunction in March. However, a D.C. Circuit panel upheld the designation 2-1 in late September under a separate statute. The dispute remains unresolved.

In June, the Commerce Department went further. It ordered access to Fable 5 and Mythos 5 suspended for any foreign national worldwide, including Anthropic's own employees. 

The company could not filter by nationality in real time, so it disabled both models globally within hours. Commerce lifted the controls on June 30. The FT reports revenue growth slowed in June.

No prior technology IPO has asked investors to underwrite a regulatory kill switch of that scope. The geostrategic offset is timing. 

Anthropic would list before OpenAI, which is leaning toward 2027, and well before DeepSeek, which targets Shanghai's STAR Market in the second quarter of 2027.

Governance Is the Structural Discount

Anthropic is a Delaware public benefit corporation. Its charter binds directors to a public mission alongside shareholder returns. 

Layered above that sits the Long-Term Benefit Trust, five financially disinterested trustees whose appointees became a board majority in April.

This inverts the usual founder-control playbook. Founders did not entrench themselves. They ceded long-horizon authority to outsiders who hold no equity. 

Public buyers get economics and a vote that cannot elect the controlling directors.

The board reflects the transition to public-company scale. Reed Hastings is there with Chris Liddell, the ex-Microsoft CFO who was responsible for the relisting of General Motors (GM).

Vas Narasimhan, CEO of Novartis (NVS), came on board in April through a trust appointment. Pricing of mission governance will depend on the wording in the S-1, either through a durability premium or a control discount by institutional investors.

Technology, Patents, and Agent Risk

Margin expansion depends on inference efficiency, which explains the Decart talks.

Risk Vector	Current Status	Investor Implication
Decart acquisition	Talks reported at roughly $6 billion; Anthropic walked away in September	No acquired chip-agnostic inference stack; efficiency gains must come in-house
Patent litigation	UTRF suit filed in Delaware in July, two patents	First patent case against Anthropic, injunction sought
Copyright	$1.5 billion author settlement approved July 20	Largest known settlement of its kind, cash already committed
Agent safety	UK AISI logged 19 unsanctioned actions across 122 runs	17 came from Mythos 5, on the live internet

Decart's optimization stack runs across Nvidia GPUs, Google TPUs, and Amazon Trainium. The company reports agentic inference above 1,600 tokens per second against an industry average near 200. Nvidia and Amazon both circled the asset. Bloomberg reported on September 8 that Anthropic walked away after due diligence. 

The security disclosure is more consequential than the litigation. The UK AI Security Institute documented an agent creating fake identities to pressure an open-source maintainer into approving malicious code. 

Safeguards had been reduced to measure maximum capability. The institute identified no resulting real-world harm. It also called the deception unprompted and emergent.

The Pharmaceutical Option Is Real but Unpriced

Anthropic launched Claude Science on June 30 and announced internal preclinical programs for neglected diseases.

Bristol Myers Squibb (BMY) rolled out Claude to more than 30,000 employees in May, and Sanofi (SNY) uses Claude in their development workflows. Narasimhan's board seat ties the strategy to the sector directly.

None of this contributes meaningful revenue today. It is optionality, and optionality on a $2 trillion base is thin.

Closing Thoughts

Financial disclosure is truly robust, and margin inflection is the single most important data point in AI this year.

The valuation debate is a different argument. At 20x forward revenue based on investor-modeled projections, the valuation presumes that the growth curve is linear.

Monitor four items. First, whether audited S-1 figures confirm the preliminary numbers. Second, whether the Pentagon designation is resolved before pricing.
 Third, whether Anthropic finds another route to cheaper inference after Decart. Fourth, whether SpaceX stays above its offering price into the fall, because that tape sets the risk appetite Anthropic will inherit.

On the date of publication, Usi Jacobi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes.